Oxford-ZEISS advances breakthrough live-cell imaging platform for next-gen drug discovery
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
As part of the deal, Red Nucleus also gains indirect ownership of the company’s Indian arm
Industry, policymakers focus on AI-led regulatory harmonisation, FTAs, MSME support and market expansion as exports touch $28.29 billion till February FY26
Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows
The Clear Lake facility marks Clariant’s first U.S. site dedicated to PEG excipient production
Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
Subscribe To Our Newsletter & Stay Updated